Several peptides for cancer are proven, FDA-approved drugs: leuprolide and degarelix for prostate cancer, octreotide for neuroendocrine tumors, and the radioactive peptide Lu-177 dotatate, which kept 65.2% of patients with advanced midgut neuroendocrine tumors free of progression at 20 months versus 10.8% on high-dose octreotide.[6] In contrast, “anticancer” peptides sold online, such as PNC-27, have only lab data and no human trials.[8] Choosing unproven treatments instead of standard care is linked to a much higher risk of death.[10]
This guide separates approved cancer drugs from research compounds. For background on what peptides are, see our peptide basics hub.
Evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Leuprolide (Lupron and others) | FDA-approved for this use | Testosterone suppression in 96.4% over a year (comparator arm)[2] | Approved 1985[1] | — |
| Degarelix (Firmagon) | FDA-approved for this use | Testosterone suppression in 97-98%, faster than leuprolide[2] | Approved 2008[3] | — |
| Octreotide (Sandostatin and others) | FDA-approved for this use | Time to tumor progression 14.3 vs 6 months in midgut NETs[4] | Approved 1988[5] | — |
| Lu-177 dotatate (Lutathera) | FDA-approved for this use | 65.2% vs 10.8% progression-free at 20 months[6] | Approved 2018 for SSTR-positive GEP-NETs[7][12] | — |
| PNC-27 | Animal or lab only | Kills cancer cells in lab dishes[8] | Not approved | PNC-27 |
| FOXO4-DRI | Animal or lab only | Cleared senescent cells in mice[9] | Not approved | FOXO4-DRI |
| Thymosin alpha-1, LL-37 | No evidence as cancer treatment | No approved cancer use in the US | Not approved[11] | Thymosin alpha-1, LL-37 |
How peptides became cancer drugs
Many tumors depend on hormones or carry receptors that a peptide can target. Drug developers have used that in three main ways:
- Hormone blocking. Some prostate and breast cancers grow in response to sex hormones. Peptide copies or blockers of gonadotropin-releasing hormone (GnRH) shut down that hormone signal.
- Receptor targeting. Many neuroendocrine tumors have somatostatin receptors on their surface. Somatostatin-like peptides such as octreotide bind to them.
- Delivering radiation. Attaching a radioactive atom to a tumor-seeking peptide carries radiation straight to cancer cells.
Our guides to peptide radiotracers and peptide-drug conjugates cover the targeting approaches in more depth, and the FDA-approved peptides list puts them in context.
Approved peptide drugs for prostate cancer
Leuprolide is a GnRH agonist, a modified version of a 10-amino-acid brain hormone. Given continuously, it overstimulates and then shuts down the pituitary signal that drives testosterone. FDA first approved leuprolide (Lupron) in 1985.[1] Because it causes a brief testosterone surge at first, doctors may add an anti-androgen at the start.
Degarelix is a GnRH antagonist: it blocks the receptor directly, with no surge. In a 12-month phase 3 trial of 610 men with prostate cancer, degarelix kept testosterone at castration levels in 97.2% to 98.3% of patients, versus 96.4% on leuprolide. By day 3, testosterone was suppressed in about 96% on degarelix and in none on leuprolide. Injection-site reactions were much more common with degarelix (40% vs under 1%).[2] FDA approved Firmagon in 2008.[3]
Common side effects of hormone therapy include hot flashes, lower libido, fatigue and bone loss. See our peptides and prostate health guide for more.
Approved peptides for neuroendocrine tumors
Octreotide copies somatostatin, a hormone that switches off many other hormones. It was approved in 1988 (Sandostatin).[5] In the PROMID trial, long-acting octreotide extended median time to tumor progression to 14.3 months from 6 months on placebo in metastatic midgut neuroendocrine tumors.[4]
Lu-177 dotatate links a somatostatin-like peptide to radioactive lutetium-177. In NETTER-1, among patients with advanced midgut neuroendocrine tumors, 65.2% on Lu-177 dotatate were progression-free at 20 months versus 10.8% on high-dose octreotide, and the response rate was 18% versus 3%. Serious drops in blood counts occurred in fewer than 10%.[6] Lutathera was approved in 2018 and is now indicated for adults and children 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.[7][12]
Research peptides with no human cancer evidence
These compounds are often promoted online as cancer treatments. None has human trial evidence for cancer:
- PNC-27 is a lab-made peptide designed to bind HDM-2, a protein found on the membranes of some cancer cells. In lab experiments, it punched holes in cancer cell membranes and damaged their mitochondria.[8] We found no registered human trial.
- FOXO4-DRI was designed to make aging (senescent) cells self-destruct. In mice, it countered some damage from the chemotherapy drug doxorubicin and features of aging.[9] It has not been tested as a cancer treatment in people.
- Thymosin alpha-1 and LL-37 are immune peptides sometimes marketed for cancer. Neither is approved for cancer in the US, and FDA lists both among compounding substances whose nominations raised safety concerns.[11]
Lab and mouse results often fail in humans. Our guides on why animal peptide studies don’t translate and how to read peptide research explain why.
Why unproven cancer treatments are dangerous
The biggest risk is not a side effect of the peptide itself but what it replaces. In a US study of 281 people with nonmetastatic breast, prostate, lung or colorectal cancer who chose alternative medicine instead of conventional treatment, the risk of death was 2.5 times higher than in matched patients who received standard care. For breast cancer, the risk was 5.7 times higher.[10]
Other concerns:
- Unknown contents. Research peptides are not checked for purity, sterility or dose. People with low immunity from chemotherapy are especially vulnerable to infections from contaminated injections. See our counterfeit peptides guide.
- Interactions. Untested compounds could interfere with chemotherapy, hormone therapy or immunotherapy.
- Cost and false hope. Unproven treatments can be expensive and delay effective care.
How strong is the evidence?
Questions to ask your oncologist
- Is a hormone or peptide-based therapy part of standard care for my cancer?
- Am I a candidate for a clinical trial, including peptide vaccine or radiotherapy trials?
- Are any supplements or peptides I take safe with my treatment?
- Who can I contact if I have new symptoms between visits?
